Regen BioPharma Inc (RGBP)

[cvinvestor]

Outlook brighter and more reliable than ever.

Those selling on today's news can only be because they were hoping for short term miracles and the regular updates are below their big pharma buyout expectations. Because never before in the past 2 years have we had a reliable access to news, transparency - only the hope of a home run from the 9 hitter that would change the game somehow.

I don't know if others see it, but believe it or not, RGBP is growing up! It's becoming a real company and I mean it. From the 6 possible scenarios I posted previously, the PRs since then to me confirm that we have aspects of all scenarios from 2 through 6. While no scenario prediction is perfect , I see the following elements of several coming together and those selling today are very short sighted as I'm more at peace for the long run than I ever was before:

From scenario 2, we have the company creating a track record of behaving like a real business (full time scientists, in-house research and experiments in their own leased labs, regular PRs to update investors on the actions of the company which can build confidence and trust that the company will be transparent).

From scenario 3, RGBP is about to turn the corner on using C. Ichim's research and acquired patents to prepare a new IND within 2015.

From scenario 4, most of the scenario is confirmed with the exception that we don't know if this is in preparation of a shares sale to raise more funds or whether the "Angel" donors have already covered all the necessary anticipated expenses through the end of 2015... and therefore the concentration for 2015 is to advance all the INDs through the necessary GLP studies (contracted for money outside) while the Ichims continue to progress further research on the current promising non INDs for cancer cell differentiation.

From scenario 5, I don't think international JV is on the table, but we did get news of FDA approval for HemaXellerate safety protocol GLP trials, so that is big for 2015 anticipated approval for human trials - concrete step forward after almost a half year of waiting.

From Scenario 6, we have HemaX protocol approval and I would expect the same for dCellVax within the next month UNLESS the research on NR2F6 is so synergetic with dCellVax that they are waiting to possibly introduce a modified IND that is dCellVax working in combination with NR2F6 target for a more potent and successful treatment for GLP safety experiments and a more promising IND.

All in all, the future is looking more secure with higher potential for success of RGBP as a company today than it ever was in the past 6 months.

It is actually starting to perform and look like a real bio pharma company. Not day to day exciting. Not keeping us on edge of our chairs in hope for miraculous news that Koos alone swung a deal to be bought out for $10/share even though he had nothing but potential in the bag. Instead, there is hope for 2015 as foundations are in and bricks are being laid for real success with people in place to guide us to some real IND approvals.

But people, it takes time to get all this accomplished. Let's see how we feel around the fourth of July (If big things happen before that, I'm okay with that because my shares are in place).

2. Company has been rather stagnated and hoping new hires and people will help to start bringing the company forward. (No major news around the corner, just starting the process of regular updates to act like a real business)

3. RGBP is about to turn the corner with the new NR2F6 breakthrough and has had interest and guarantees of some kind of partnership to fund not only NR2F6, but advance dCellVax and HemaX as well.

4.Most probable: (Why the hiring and divy all at once?) RGBP is out of cash and needs cash to conduct GLP as well as future clinical trials. With NR2F6 2nd Generation strength concept proven in vitro, RGBP sees great potential and wants to develope it quickly, so they believe timing is right (Feb seems to be the historic month for moves up) to raise funds. Therefore, T&C Ichim are formal hires, Caven comes on to direct raising funds and I think the divvy as others mentioned is to boost price from .10 to over .50, clear out any mishandling of shares trading and then RGBP announces a sale of 20M-50M shares somewhere between .30-.50 which will raise 6M-25M in cash. Think about it, who on this board wouldn't think the company would be better situated with 6-25 million in cash, 3 possible candidates in the pipeline and a 100 M share O/S? Stock wouldn't stay at .30 even if investors shares were sold that low. Suddenly, RGBP would appear on paper and to others as a legit company with cash and potential instead of the one man show it has been.

5. International JV/Partnership to explore development of NR2F6 target (plus HemaX I and dCellVax) that moves forward without need of FDA approval because it would be an exclusive rights application for foreign areas only. Unless we get news that FDA has approved safety testing protocols for HemaX and dCellVax, or better, that they have and tests have been underway with positive results to date (a slim possibility), all 3 products are on hold until FDA finalizes its standards for cell safety judging. However, given C. Ichim's presentation in Jan at ASH with over 100 countries represented, it is possible that an international entity wants to partner/license/buy out the IP for development elsewhere, leaving all US rights still in the hands of RGBP, but allowing the research and human trials to go forward elsewhere, which if successful, would build interest and buyout of RGBP in US for the future.

6. BEST case scenario: RGBP has finally received word that HemaX protocol for safety trials will be approved, dCellVax will also get Green Light and the development of NR2F6 is so positive, that they are positioning themselves against an outright takeover and setting structure for an advantageous partnership once the news of these 3 developments all hit at once.